1. Home
  2. MMI vs IOVA Comparison

MMI vs IOVA Comparison

Compare MMI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMI

Marcus & Millichap Inc.

HOLD

Current Price

$28.15

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.46

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMI
IOVA
Founded
1971
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
968.6M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MMI
IOVA
Price
$28.15
$2.46
Analyst Decision
Sell
Buy
Analyst Count
2
12
Target Price
$29.00
$10.45
AVG Volume (30 Days)
440.2K
10.2M
Earning Date
11-07-2025
11-06-2025
Dividend Yield
1.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$751,284,000.00
$250,425,000.00
Revenue This Year
$11.94
$60.94
Revenue Next Year
$15.59
$60.85
P/E Ratio
N/A
N/A
Revenue Growth
20.74
175.62
52 Week Low
$27.35
$1.64
52 Week High
$41.94
$8.15

Technical Indicators

Market Signals
Indicator
MMI
IOVA
Relative Strength Index (RSI) 43.13 57.65
Support Level $27.38 $2.08
Resistance Level $28.99 $2.32
Average True Range (ATR) 0.82 0.14
MACD -0.07 0.02
Stochastic Oscillator 33.05 73.08

Price Performance

Historical Comparison
MMI
IOVA

About MMI Marcus & Millichap Inc.

Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: